Onkológia 2/2023
Advances in the systemic treatment of non-small cell lung cancer
Over the past decade, targeted therapy for oncogene-driven NSCLC and immune checkpoint inhibitors for nononcogene-driven NSCLC, have greatly improved the survival and quality of life for patients with unresectable NSCLC. Increasingly, these biomarker-guided systemic therapies given before or after surgery have been used in patients with early-stage NSCLC In this article, we will review several important recent studies in the field of neoadjuvant treatment, adjuvant treatment and treatment of advanced disease.
Keywords: non-small cell lung cancer, targeted treatment, immunotherapy, neoadjuvant, adjuvant treatment
